



PATENT

Attorney Docket No.: 8117-14 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent application of :  
Graham McCreath, et al. :  
Serial No.: 09/814,371 : Group Art Unit: 1651  
Filed: March 22, 2001 : Examiner: Jon P. Weber  
For: PURIFICATION OF FIBRINOGEN FROM : Confirmation No.: 4297  
FLUIDS BY PRECIPITATION AND  
HYDROPHOBIC CHROMATOGRAPHY

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith are copies of the references listed in the accompanying Form PTO-1449.

The Examiner is respectfully requested to review the items listed on the attached form and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate Form 1449, and return one copy to the undersigned.

09/23/2004 BABRAHA1 00000012 09814371


02 FC:1806

180.00 OP

PHIP\380344\1

**CERTIFICATE OF MAILING  
UNDER 37 C.F.R. 1.8A**

I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date indicated below, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


  
Signature of person mailing page:


DATE: 09/20/2004  
Shannon R. Smith  
Type or print name of person

This Statement should not be construed as a representation that the cited references are material or that more relevant prior art does not exist.

The fee (\$180) is submitted herewith pursuant to 37 C.F.R. 1.17(p). The Commissioner is hereby authorized to charge any underpayment of that fee, or any other fee associated with this communication, including any necessary fees for extension of time, or credit any overpayment to Deposit Account No. 50-0573.

Respectfully submitted,  
GRAHAM McCREATH, et al.

By:   
DANIEL A. MONACO  
Reg. No. 30,480  
Drinker Biddle & Reath LLP  
One Logan Square  
18<sup>th</sup> and Cherry Streets  
Philadelphia, PA 19103-6996  
Tel. (215) 988-3312  
Fax. (215) 988-2757  
Attorney for Applicants

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT</b> 	<b>ATTY. DOCKET NO.</b> 8117-14 US	<b>SERIAL NO.</b> 09/814,371
	<b>APPLICANT:</b> GRAHAM McCREATH, et al.	
	<b>FILING DATE</b> March 22, 2001	<b>GROUP</b> 1651

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
								NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AA	Izabella Lipinska et al., "Fibrinogen Heterogeneity In Human Plasma. Electrophoretic Demonstration And Characterization Of Two Major Fibroinogen Components", <i>Journal of Laboratory &amp; Clinical Chemistry</i> , 84 (4): 509-516 (1974)
AB	Jacek Hawiger, "Adhesive Ends Of Fibrinogen And Its Antiadhesive Peptides: The End Of A Saga?" <i>Seminars in Haematology</i> , 32 (2): 99-109 (1995)
AC	Victor Marder & N Raphael Shulman, "High Molecular Weight Derivatives Of Human Fibrinogen Produced By Plasmin", <i>Journal of Biological Chemistry</i> , 244 (8): 2120-2124 (1969)
AD	C. Rupp et al., "Fractionation Of Plasmic Fibrinogen Digest On Lysine-Agarose, Isolation Of Two Fragments D, Fragment E And Simultaneous Removal Of Plasmin", <i>Thrombosis Research</i> , 21: 117-121 (1982)
AE	G Markus et al., Casein, "A Powerful Enhancer Of The Rate Of Plasminogen Activation", <i>Fibrinolysis</i> , 7: 229-236 (1993)
AF	David Sierra, "Fibrin Sealant Adhesive Systems: A Review Of Their Chemistry, Material Properties And Clinical Applications", <i>Journal of Biomaterials Applications</i> , 7: 309-352 (1993)
AG	B. Holm et al., "Purification And Characterization Of 3 Fibrinogens With Different Molecular Weights Obtained From Normal Human Plasma", <i>Thrombosis Research</i> , 37: 165-176 (1985)

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	